Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.
Patient KW, a 36-yr-old male renal transplant recipient, received transplant acceptance-inducing cells (TAICs) as an adjunct immunosuppressive therapy. In the weeks post-transplantation, the patient's conventional immunosuppressive treatment was gradually minimized, such that, from the 21st wk post-transplantation onwards, the patient was stably maintained on tacrolimus monotherapy. Treatment with TAICs was without complication, both at the time of administration and in the four-yr follow-up period. It is concluded that the production and administration of TAICs to recipients of kidney transplants from deceased donors is technically feasible.
Hutchinson
James A
JA
Department of General and Cardiothoracic Surgery, Laboratory for Transplantation Research, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany. james.hutchinson@cantab.net
Gövert
Felix
F
Riquelme
Paloma
P
Bräsen
Jan Hinrich
JH
Brem-Exner
Beate G
BG
Matthäi
Martina
M
Schulze
Maren
M
Renders
Lutz
L
Kunzendorf
Ulrich
U
Geissler
Edward K
EK
Fändrich
Fred
F
D000328:Adult; D002102:Cadaver; D064987:Cell- and Tissue-Based Therapy; D005240:Feasibility Studies; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016559:Tacrolimus / Q000627:therapeutic use; D014019:Tissue Donors; D019172:Transplantation Conditioning; D023001:Transplantation Tolerance / Q000276:immunology*
D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016559:Tacrolimus